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Abstract 
previous work has demonstrated the importance of the protein kinase C (PKC) system in regulating glioma growth, and has led to clinical trials 
utilizing PKC inhibitors as adjuncts in the therapy of patients harboring malignant gliomas. This study was performed to explore the possibility that 
inhibition of PKC in gliomas was triggering an apoptosis signal. Glioma cell lines were treated with PKC inhibitors staurosporine (10 nM), and 
tamoxifen (10 PM). DNA from cells treated with each of these drugs exhibited a ‘ladder’ pattern of oligonucleosome-sized fragments characteristic 
of apoptosis, thus suggesting that in glioma cells, these drugs may be cytocidal in action. 
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1. Jntruduction 
Apoptosis, or programmed cell death, is closely and 
directly linked to the proliferative capacity of cells. Some 
malignant cells express various components of the apop- 
totic program, and may be susceptible to various phar- 
macological triggers which activate the cell death path- 
way. In different experimental systems, perturbation of 
protein kinase C (PKC) activity has been shown to either 
induce or repress apoptosis [l]. 
grammed cell death (i.e. apoptosis) was occurring as a 
result of treatment of malignant glioma cells with the 
PKC inhibitors. 
2. Materials and methods 
2.1. Glioma cell lines and reagents 
The previously characterized human malignant glioma cell lines 
Al72 
Malignant gliomas possess very high PKC activity 
when compared to non-transformed glia, which is 
strongly correlated to the growth rates of these tumor 
cells in vitro [24]. Surgically-resected frozen human gli- 
oma specimens also display elevated PKC activity within 
the range of activity measured in established glioma lines 
[3]. This elevated PKC activity may function as a target 
for inhibition of glioma growth in vitro [5-71, and is 
currently being evaluated with some success in clinical 
trials for use as a chemotherapeutic target in vivo [8-lo]). 
and U87-MG were used in this study (obtained from the ATCC). Lines 
were maintained in 25 cm* tissue culture flasks, in medium consisting 
of Eagle’s MEM (minimal essential medium) supplemented with 10% 
bovine fetal serum (FCS), gentamicin (20 @ml), glutamine, pyruvate 
(1 mM), dextrose (0.1%) and essential amino acids buffered to a pH of 
7.0 (all medium constituents were purchased from Gibco, Grand Island, 
NY). Cells were grown at 37’C in a humidified 5% CO* incubator. All 
lines were routinely tested for mycoplasma contamination and pas- 
saged regularly. Cultures were treated with the following commercially 
available drugs: staurosporine (Calbiochem, La Jolla CA), tamoxifen 
(ICI Pharmaceutical, Wilmington, DW), human recombinant tumor 
necrosis factor-alpha (Boehringer Mannheim Biochemica, Indianapo- 
lis, IN), PMA (Sigma, St. Louis, MO). 
Surprisingly, some patients have exhibited dramatic 
clinical responses to the administration of oral high-dose 
tamoxifen, which is known to inhibit PKC in these and 
other cells [7,9,10,11]. Such observations have led us to 
postulate that the nature of such treatment may be more 
than the mere inhibition of cell growth (cytostasis). Thus, 
the present study was performed to determine if pro- 
2.2. In vitro [‘H]thymidine uptake 
*Corresponding author. Fax: (1) (213) 342 5950. 
Abbreviations: PKC, protein kinase C, ATCC, American Type Culture 
Collection; FCS, fetal calf serum; MEM, minimal essential medium; 
PBS, phosphate-buffered saline; TNF-a, tumor necrosis factor-alpha; 
PMA, 4-phorbol-12-myristate-I 3 acetate; SDS, sodium dodecyl sulfate. 
Our method for determining rates of glioma proliferation has been 
previously published [5]. Following passage, each cell line was seeded 
at a density of 104 cells in 40 ~1 of medium on 12 mm glass cover slips 
placed in 24well culture plates. Coverslips were previously coated with 
10 &nl poly-r_-lysine to facilitate cell adherence. Twelve hours later, 
after adequate time for cells to adhere to the cover slips, the wells were 
flooded and washed with PBS. After addition of 1 ml of feeding medium 
(containing 10% FCS) to each well, each of the PKC inhibitors was then 
added to the wells at predetermined concentrations in replicates of 
three. At specified intervals, wells were pulsed with 1 PCi [3H]thymid- 
i&ml for a period of 6 h prior to harvest. To measure thymidine 
incorporation, the cover slips with adherent cells were washed 4 times 
with PBS and placed in scintillation vials containing 5 ml of scintillation 
fluid (Cytoscint, ICN Chemical, Irvine, CA) for determination in a 
@ounter. It has been previously demonstrated that uptake of [‘Hjthy- 
midine into cells by this technique is a reliable index of DNA synthesis 
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2.3. DNA fragmentation assay 
Following treatment with the PKC modulators, washed cell pellets 
were resuspended in lysis buffer (0.5% SDS, 0.1 M NaCl, 10 mM 
EDTA, 0.01 M Tris-HCl, pH 8.0) in the presence of 0.1 mg/ml pro- 
teinase K for 18-24 h at 37°C. Samples were extracted twice with 
phenol:chloroform/isoamyl alcohol and precipitated by the addition of 
1110 volume 2 M sodium acetate and 2.5 volumes of ethanol. After 
resuspension in 10 mM Tris, 1 mM EDTA, pH 7.4, samples were 
treated with DNase-free RNase for 2 h at 37°C. After reextraction and 
reprecipitation, samples were dissolved in 10 mM Tris, 1 mM EDTA, 
pH 7.4. DNA concentration was determined by Azm measurements 
using a Beckman DU-640 spectrophotometer. Equal amounts of DNA 
were electrophoresed on a 1.2% agarose gel containing 0.5 mg/ml ethid- 
ium bromide and visualized by UV fluorescence. 
3. Results and discussion 
Recent clinical studies have demonstrated efficacy 
using orally administered tamoxifen in patients harbor- 
ing recurrent malignant gliomas [&lo]. When adminis- 
tered in high dosages, clinical response or stabilization 
has been noted in 8/18 patients (44%) over a median 
follow-up period of 16 months ([9]; WTC, unpublished 
updated data). Such optimistic results in these patients 
indicate potential for this type of therapy; as such the 
nature of tumor inhibition by anti-PKC therapy is clin- 
ically relevant. 
As has been demonstrated in previous reports 
[2,3,6,7], [3H]thymidine incorporation in both Al72 and 
U87 glioma cells was decreased in a dose-related manner 
by the addition of staurosporine or tamoxifen for a 48 
h period (Fig. 1). Treatment of Al72 glioma cells with 
10 nM staurosporine or 10 PM tamoxifen for 72 h re- 
sulted in significant cell detachment. Floating cells were 
permeable to trypan blue dye indicating that they had 
lost viability. After adherent and floating cells were col- 
lected and pooled, DNA was purified and extracted by 
agarose gel electrophoresis. The results in Fig. 2 reveal 
a classical ladder pattern of oligonucleosomal-sized frag- 
mented DNA, which is a frequent characteristic of apop- 
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tosis, for both staurosporine- and tamoxifen-treated 
Al72 cells. In contrast, no significant DNA degradation 
was observed for untreated cells; the comparable intensi- 
ties of high molecular weight main band DNA observed 
in all samples serving as an internal control for equal 
loading of DNA. As a positive control for the induction 
of apoptosis, Al72 cells were treated with 100 ng/ml 
TNF-a. We have also observed the induction of apopto- 
sis in U87 glioma cells by both staurosporine and tamox- 
ifen (results not show). Although the gel electrophoresis 
assay for apoptosis yields qualitative, rather than quanti- 
tative data, the apoptotic response of Al72 cells treated 
with TNF-a appeared more pronounced than that ob- 
served for either staurosporine- or tamoxifen-treated 
cells. The induction of apoptosis by staurosporine or 
tamoxifen does not appear to be a simple response to 
growth inhibition, as Al72 cells cultured for 7 days in 
serum-free medium did not exhibit DNA fragmentation 
(data not shown). 
Previously, we have observed that chronic treatment 
with PMA downregulates PKC activity in glioma cells 
[3]. If the induction of apoptosis in glioma cells by stau- 
rosporine or tamoxifen results from their action on PKC, 
then chronic treatment with PMA should also trigger 
apoptosis. The results in Fig. 3 demonstrate that U87 
glioma cells treated with either 100 nM or 1 ,uM PMA 
for 72 h underwent apoptosis, as revealed by the DNA 
fragmentation assay. This fmding provides additional 
support for our hypothesis that perturbation of PKC 
activity in glioma cells both inhibits proliferation and 
induces apoptosis. 
Results from the present study indicate that the PKC 
inhibitors staurosporine and tamoxifen are strong in- 
ducers of apoptosis in cultured glioma cells. Of direct 
relevance to our findings is the recent report of Knox et 
al. [12] showing that staurosporine induced apoptosis in 
group-I Burkitt’s lymphoma cells, when used at con- 
centrations relatively selective for PKC activity. Our ob- 
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Fig. 1. The PKC inhibitors staurosporine and tamoxifen decrease thymidine uptake in cultured glioma cells. Staurosporine (10 nM) and tamoxifen 
(10 PM) were added for a period of 48 h to cultured glioma cells in mid-logarithmic growth phase. Thymidine uptake is decreased by both of the 
treatments. Shown here are two representative experiments with established human glioma cell lines U87 and A172. Values are mean of triplicates 
+ standard error of the mean (**indicates values significantly different than controls using Student’s t-test; P < 0.01). 
NT Couldwell et al. IFEBS Letters 345 (1994) 43-46 45 
servation is also consistent with the recently published 
study by Obeid et al. [13], whom noted that ceramide- 
induced apoptosis could be blocked by the administra- 
tion of PMA, an activator of PKC. High PKC activity 
in glioma cells may prevent the execution of a latent cell 
death program. Inhibition of PKC activity by stauro- 
sporine or tamoxifen may relieve the block and promote 
apoptosis in glioma cells. 
Not all studies are consistent with the hypothesis that 
PKC is a negative regulator of apoptosis. Some reports, 
in accord with our findings for glioma cells, describe the 
induction of apoptosis by PMA [14,15]. Since PMA can 
either activate or down regulate PKC activity depending 
on the concentration used and the exposure time, inter- 
pretation of its effects should be made with caution 
[3,15]. Furthermore, ‘PKC activity’ may reflect the con- 
tribution from as many as nine isoforms which display 
characteristic patterns of tissue distribution and subcel- 
lular localization [16-181. The specific PKC isoform(s) 
which is the target for PMA, staurosporine, or tamoxifen 
in studies on apoptosis remains to be identified. 
In addition to displaying high levels of PKC activity, 
glioma cells also express a number of proto-oncogenes 
which may participate in the control of cell proliferation 
and apoptosis. In a survey of 20 glioma tumor cell lines, 
all were found to express sign&ant levels of the nuclear 
proto-oncogene c-myc [19]. Deregulated or constitutive 
expression of c-myc has been shown to facilitate apopto- 
sis in malignant cells subjected to conditions which re- 
strict growth or impose a cell-cycle block [20-231. The 
induction of apoptosis in glioma cells after growth arrest 
by PKC inhibitors, therfore, may involve the participa- 
tion of c-myc. The clinical implication of this study is that 
administration of PKC inhibitors may induce pro- 
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Fig. 2. Induction of DNA fragmentation in Al72 and U87 glioma cells 
by staurosporine and tamoxifen. Treatment of glioma cells with PKC 
inhibitors and DNA isolation are described in Materials and Methods. 
DNA isolated from Al72 cells in the absence of PKC inhibitors (Lane 
“C”), or with 10 nM staurosporine (Lane “ST”), or 10 PM tamoxifen 
(Lane “TAM”) was electrophoresed in 1.2% agarose and stained with 
100 @ml TNF-a (Lane “TNF”). The sizes of oligonucleosomal frag- 
ments were determined by comparison to DNA size markers (Lane 
“M”). Arrow heads point to the location of oligonucleosomal frag- 
ments. 
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Fig. 3. Induction of DNA fragmentation in US7 glioma cells by PMA. 
Treatment of glioma cells with PMA and DNA isolation are described 
in section 2. DNA isolated from U87 cells in the absence of PMA (Lane 
‘C’) or with 100 nM PMA (Lane ‘100 &I’) or 1 PM PMA (Lane ‘1 PM 
PMA’) was electrophoresed in 1.2% agarose and stained with ethidium 
bromide. The sires of oligonucleosomal fragments were determined by 
comparison to DNA size markers (Lane ‘M’). Arrow heads point to the 
location of oligonucleosomal fragments. 
grammed cell death in susceptible glioma cells, produc- 
ing a cytocidal rather than a mere cytostatic effect. 
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